M
M. Stella Dolci
Researcher at Université libre de Bruxelles
Publications - 9
Citations - 4887
M. Stella Dolci is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Disease. The author has an hindex of 2, co-authored 2 publications receiving 4569 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal ArticleDOI
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Lynnette Fernandez-Cuesta,Catherine Oakman,Priscila Falagan-Lotsch,Ke-seay Smoth,E. Quinaux,Marc Buyse,M. Stella Dolci,Evandro de Azambuja,Pierre Hainaut,Patrizia Dell'Orto,Denis Larsimont,Prudence A. Francis,John Crown,Martine Piccart-Gebhart,Giuseppe Viale,Angelo Di Leo,Magali Olivier +16 more
TL;DR: The prognosis and predictive values of TP53 somatic mutations in the BIG 02-98 randomized phase III trial in which women with node-positive breast cancer were treated with adjuvant doxorubicin-based chemotherapy with or without docetaxel were explored.
Journal ArticleDOI
Circulation of SARS-CoV-2 Variants among Children from November 2020 to January 2022 in Trieste (Italy)
M. Stella Dolci,Lucia Signorini,Carolina Cason,Giuseppina Campisciano,Paolo Kunderfranco,Elena Pariani,Cristina Galli,Vincenzo Petix,Pasquale Ferrante,Serena Delbue,Manola Comar +10 more
TL;DR: Attention should be devoted to the pediatric population to prevent the spread of new SARS-CoV-2 variants in an unvaccinated and predominantly naive population to report here in a pediatric population for the first time.
Journal ArticleDOI
In Vitro SARS-CoV-2 Infection of Microvascular Endothelial Cells: Effect on Pro-Inflammatory Cytokine and Chemokine Release
M. Stella Dolci,Lucia Signorini,Sarah D'Alessandro,Federica Perego,Silvia Parapini,Michele Sommariva,Donatella Taramelli,Pasquale Ferrante,Nicoletta Basilico,Serena Delbue +9 more
TL;DR: The data indicate that in vitro microvascular endothelial cells are susceptible to SARS-CoV-2 infection but slightly contribute to viral amplification, however, Sars-CoVs infection might trigger the increase of pro-inflammatory mediators.
Journal ArticleDOI
Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey
Estefanía Calvo-Álvarez,M. Stella Dolci,Federica Perego,Lucia Signorini,Silvia Parapini,Sarah D'Alessandro,Luca Denti,Nicoletta Basilico,Donatella Taramelli,Pasquale Ferrante,Serena Delbue +10 more
TL;DR: The (controversial) journey of these old antiparasitic drugs to combat the human infection caused by the novel coronavirus SARS-CoV-2 is reviewed.